GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » United Laboratories International Holdings Ltd (HKSE:03933) » Definitions » Equity-to-Asset

United Laboratories International Holdings (HKSE:03933) Equity-to-Asset : 0.59 (As of Jun. 2024)


View and export this data going back to 2007. Start your Free Trial

What is United Laboratories International Holdings Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. United Laboratories International Holdings's Total Stockholders Equity for the quarter that ended in Jun. 2024 was HK$14,561 Mil. United Laboratories International Holdings's Total Assets for the quarter that ended in Jun. 2024 was HK$24,573 Mil. Therefore, United Laboratories International Holdings's Equity to Asset Ratio for the quarter that ended in Jun. 2024 was 0.59.

The historical rank and industry rank for United Laboratories International Holdings's Equity-to-Asset or its related term are showing as below:

HKSE:03933' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.36   Med: 0.42   Max: 0.61
Current: 0.59

During the past 13 years, the highest Equity to Asset Ratio of United Laboratories International Holdings was 0.61. The lowest was 0.36. And the median was 0.42.

HKSE:03933's Equity-to-Asset is ranked worse than
50.72% of 1043 companies
in the Drug Manufacturers industry
Industry Median: 0.6 vs HKSE:03933: 0.59

United Laboratories International Holdings Equity-to-Asset Historical Data

The historical data trend for United Laboratories International Holdings's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Laboratories International Holdings Equity-to-Asset Chart

United Laboratories International Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.43 0.58 0.57 0.56 0.61

United Laboratories International Holdings Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.56 0.56 0.58 0.61 0.59

Competitive Comparison of United Laboratories International Holdings's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, United Laboratories International Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


United Laboratories International Holdings's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, United Laboratories International Holdings's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where United Laboratories International Holdings's Equity-to-Asset falls into.



United Laboratories International Holdings Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

United Laboratories International Holdings's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=13929.031/22988.148
=0.61

United Laboratories International Holdings's Equity to Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

Equity to Asset (Q: Jun. 2024 )=Total Stockholders Equity/Total Assets
=14560.738/24573.32
=0.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


United Laboratories International Holdings  (HKSE:03933) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


United Laboratories International Holdings Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of United Laboratories International Holdings's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


United Laboratories International Holdings Business Description

Traded in Other Exchanges
Address
No. 6 Fuk Wang Street, Yuen Long Industrial Estate, New Territories, Hong Kong, HKG
United Laboratories International Holdings Ltd is a drug manufacturing company. United Laboratories is organized into three revenue streams, including Intermediate products, Bulk medicine, and Finished products. The company's Finished products segment includes antibiotic products, insulin series products, and other medicines. The vast majority of the company's revenue is derived from its Bulk medicine segment, followed by Finished products. Majority of the company's sales are generated in China, followed by Europe, India and other countries.
Executives
Heren Far East #4 Limited 2201 Interest of corporation controlled by you
Heren Far East Limited 2101 Beneficial owner
Iq Eq Services (hk) Limited 2201 Interest of corporation controlled by you

United Laboratories International Holdings Headlines

No Headlines